menu
    • menu
    [{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Sinapultide","moa":"peptides: peptides used as pulmonary surfactants","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Windtree Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"4","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"}]

    Find Clinical Drug Pipeline Developments & Deals for Sinapultide

    Menu

    Sinapultide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Windtree Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Windtree Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sinapultide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Ladenburg Thalmann & Co

                            Deal Size : $20.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotme...

                            Details : Windtree intends to use the net proceeds from this offering to advance the study of KL4 surfactant to treat COVID-19 related lung injury; istaroxime acute heart failure phase 2b start-up activities;clinical development of AEROSURF;pre-clinical studies of...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            May 22, 2020

                            Lead Product(s) : Sinapultide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Ladenburg Thalmann & Co

                            Deal Size : $20.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth